EMA Issues Updated Guidance for Transition to Low-GWP Propellants in Pharmaceutical Development

A recent paper examines the European Medicines Agency’s (EMA) updated guidance on transitioning to low global warming potential (GWP) propellants. The document aims to assist companies in aligning their development processes with regulatory requirements as they prepare for the shift to more environmentally sustainable alternatives.

The analysis highlights key aspects of the EMA’s recommendations, which focus on ensuring that pharmaceutical companies adopt efficient and effective strategies during this transition. The guidance addresses technical, regulatory, and environmental considerations associated with low-GWP propellants. By outlining these requirements, the EMA seeks to facilitate compliance while supporting broader sustainability goals within the industry.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 21, 2025

Author

Mark Chiang